Bill > A06935

This bill requires Medicaid to cover a specific type of wearable medical device that uses low-intensity, alternating electric fields applied directly to a tumor site for treating glioblastoma (an aggressive form of brain cancer) and other cancers. The coverage must be based on recommendations from medical and scientific evidence, which include three specific criteria: (1) medical devices approved or cleared by the Federal Food and Drug Administration, (2) Centers for Medicare and Medicaid Services national and local coverage determinations, and (3) clinical practice guidelines from recognized national organizations like the National Comprehensive Cancer Network or the American Society of Clinical Oncology. By amending the social services law, the bill aims to ensure that Medicaid beneficiaries have access to this innovative cancer treatment technology. The bill is set to take effect on the first of April following its enactment, providing a clear timeline for implementation of the new coverage requirement.

Health and Social Services

https://www.nysenate.gov/legislation/bills/2025/A6935